2. Immunology/Inflammation NF-κB Metabolic Enzyme/Protease Apoptosis Stem Cell/Wnt Neuronal Signaling Autophagy
  3. Interleukin Related Reactive Oxygen Species (ROS) MMP Pyroptosis Ferroptosis Notch Keap1-Nrf2 PINK1/Parkin Mitophagy Caspase Apoptosis
  4. Acetyl zingerone

Acetyl zingerone is an analog of Zingerone (HY-14621). Acetyl zingerone downregulates the expression of ROS metabolism-related genes, fibroblast senescence-related genes, keratinocyte differentiation-related genes, and IL-17A target genes. Acetyl zingerone inhibits the activities of MMP-1, MMP-3, and MMP-12, as well as the activation of NLRP3 inflammasome, pyroptosis (pyroptosis), ferroptosis (ferroptosis), cartilage destruction, and UVA-induced cyclobutane pyrimidine dimer formation. Acetyl zingerone upregulates the expression of collagen, proteoglycan, extracellular matrix glycoprotein, Notch pathway, and GPX4 gene, activates Nrf2 and HO-1, induces extracellular matrix synthesis and PINK1/Parkin-mediated mitophagy (mitophagy), and promotes chondrocyte survival. Acetyl zingerone alleviates the progression of osteoarthritis in mice. Acetyl zingerone can be used in research related to skin aging, inflammatory skin diseases, osteoarthritis, melanoma, and non-melanoma skin cancer.

For research use only. We do not sell to patients.

Acetyl zingerone

Acetyl zingerone Chemical Structure

CAS No. : 30881-23-3

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Acetyl zingerone Related Antibodies

Top Publications Citing Use of Products

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

View All MMP Isoform Specific Products:

View All Isoforms
MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8 MMP-19

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Acetyl zingerone is an analog of Zingerone (HY-14621). Acetyl zingerone downregulates the expression of ROS metabolism-related genes, fibroblast senescence-related genes, keratinocyte differentiation-related genes, and IL-17A target genes. Acetyl zingerone inhibits the activities of MMP-1, MMP-3, and MMP-12, as well as the activation of NLRP3 inflammasome, pyroptosis (pyroptosis), ferroptosis (ferroptosis), cartilage destruction, and UVA-induced cyclobutane pyrimidine dimer formation. Acetyl zingerone upregulates the expression of collagen, proteoglycan, extracellular matrix glycoprotein, Notch pathway, and GPX4 gene, activates Nrf2 and HO-1, induces extracellular matrix synthesis and PINK1/Parkin-mediated mitophagy (mitophagy), and promotes chondrocyte survival. Acetyl zingerone alleviates the progression of osteoarthritis in mice. Acetyl zingerone can be used in research related to skin aging, inflammatory skin diseases, osteoarthritis, melanoma, and non-melanoma skin cancer[1][2][3][4].

In Vitro

Acetyl zingerone alters gene expression in recombinant human epidermis, upregulating genes related to the core matrix group, Notch, and ERK1/ERK2 pathways, while downregulating inflammation-related genes, as well as genes associated with the TGF-β signaling pathway and AP-1/NF-κB[1].
Acetyl zingerone (10-200 µg/mL; 6 days) dose-dependently increases the abundance of extracellular matrix proteins per cell density in cultured human skin fibroblasts[1].
Acetyl zingerone (10 µL/cm2; once daily for 4 consecutive days) doubles the dermal collagen content in ex vivo human facial skin biopsy samples[1].
Acetyl zingerone (with 1:1 serial dilutions performed starting from a stock solution prepared by dissolving 0.1 g AZ in 1 mL DMSO; 10 min (MMP-1, MMP-3); 15 min (MMP-12)) inhibits the activities of MMP-1, MMP-3 and MMP-12 in cell-free assays, with the strongest inhibitory potency against MMP-12 (IC50 = 0.255 mg), followed by MMP-3 (IC50 = 0.505 mg) and MMP-1 (IC50 = 1.065 mg)[1].
Acetyl zingerone reverses gene expression patterns associated with fibroblast senescence, keratinocyte differentiation, and IL-17A stimulation in reconstructed human epidermis[1].
Acetyl zingerone (25-200 μM; 2-48 h) exerts a protective effect on ATDC5 chondrocytes, protecting them from LPS (HY-D1056)+ ATP (HY-B2176)-induced cytotoxic damage and restoring their proliferative capacity[2].
Acetyl zingerone (100 μM; 24 h) inhibits LPS + ATP-induced pyroptosis of ATDC5 chondrocytes by alleviating cell membrane damage, suppressing NLRP3 inflammasome activation, and reducing the expression of downstream pyroptosis-related proteins[2].
Acetyl zingerone (100 μM; 24 h) attenuates LPS + ATP-induced mitochondrial damage in ATDC5 chondrocytes by reducing ROS/mtROS production and restoring mitochondrial membrane potential and structural integrity[2].
Acetyl zingerone (100 μM; 24 h pretreatment, 24 h LPS + ATP induction) activates PINK1/Parkin-mediated mitophagy in LPS + ATP-treated ATDC5 chondrocytes[2].
Acetyl zingerone (25-100 μM; 24-48 h) increases the survival rate of primary rat chondrocytes treated with IL-1β and restores their proliferative capacity[3].
Acetyl zingerone (25-100 μM; 24 h) maintains ECM homeostasis in IL-1β-treated primary rat chondrocytes and mouse ATDC5 chondrogenic cells by upregulating aggrecan and COL2A1, and downregulating matrix-degrading enzymes and inflammatory factors[3].
Acetyl zingerone (25-100 μM; 24 h) inhibits IL-1β-induced apoptosis in IL-1β-treated primary rat chondrocytes and mouse ATDC5 chondrogenic cells by upregulating Notch1 and SOCS3 and reducing the level of activated caspase-3[3].
Acetyl zingerone (25-100 μM; 24 h) reduces IL-1β-induced ROS accumulation in primary rat chondrocytes[3].
Acetyl zingerone (100 μM; 24 h) inhibits IL-1β-induced ferroptosis in primary rat chondrocytes and mouse ATDC5 chondrogenic cells by increasing GSH levels, decreasing MDA levels, stabilizing mitochondrial structure, upregulating GPX4, and activating the Nrf2/HO-1 pathway[3].
Acetyl zingerone (25 µg/mL; administered 1-6 h post-UVA irradiation) significantly reduces the formation of dark-state cyclobutane pyrimidine dimers (dark-CPD) in melanocytes of C57BL/6 mice within the first 2 hours after UVA exposure, with an inhibition rate of approximately 82% at 1 h post-irradiation, without impairing DNA repair function or cell viability[4].
Acetyl zingerone (25-50 µg/mL; 20 min pre-incubation prior to 25 min UVA irradiation) dose-dependently reduces UVA-induced ROS production in normal human neonatal epidermal keratinocytes, with reduction rates of 35% and 46%, respectively[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Acetyl zingerone Related Antibodies

ELISA Assay[1]

Cell Line: Cultured human dermal fibroblasts
Concentration: 0, 10, 25, 50, 100, 200 µg/mL
Incubation Time: 6 day
Result: Increased protein abundance per unit cell density (P < 0.05) in a dose-dependent manner for type I, IV, and VI collagens; fibromodulin; transforming growth factor-β; fibronectin; TIMP-1; and vimentin.
Showed greater abundance with higher AZ concentrations, with significant differences from control observed at specific doses (e.g., type I collagen at 100 µg/mL, type IV collagen at 50 and 100 µg/mL).

Cell Viability Assay[2]

Cell Line: ATDC5 chondrocytes
Concentration: 25, 50, 100, 200 μM
Incubation Time: 24 h, 48 h (co-treatment with LPS + ATP); 24 h (treatment with LPS + ATP), 2 h (EdU (HY-118411) incubation)
Result: Shows no cytotoxicity at concentrations below 100 μM.
Significantly reduces cell viability at 200 μM after 24 h and 48 h.
Mitigates LPS + ATP-induced cytotoxicity, with 100 μM producing the most pronounced improvement in cell viability.
Reverses LPS + ATP-induced inhibition of chondrocyte proliferation, with 100 μM being the most effective concentration.

Cell Autophagy Assay[2]

Cell Line: ATDC5 chondrocytes
Concentration: 100 μM
Incubation Time: 24 h pretreatment, followed by 24 h LPS + ATP induction
Result: Significantly increases the expression of PINK1, Parkin, and LC3-II, and decreases p62 expression in LPS + ATP-treated chondrocytes.
Enhances PINK1 and Parkin expression, which is suppressed by chloroquine (CQ) via immunofluorescence.
Increases co-localization of Parkin and LC3B with mitochondria, enhances autolysosome formation, and promotes mitophagic clearance of damaged mitochondria; these effects are attenuated by CQ.
Reduces LPS + ATP-induced ROS and mtROS production, an effect reversed by CQ.

Apoptosis Analysis[3]

Cell Line: primary rat chondrocytes, mouse ATDC5 chondrogenic cells
Concentration: 25, 50 and 100 μM
Incubation Time: 24 h
Result: Reduced IL-1β-induced apoptosis (lower early + late apoptotic cell proportion), increased cell number, upregulated Notch1 and SOCS3 expression, and decreased the cleaved caspase-3/caspase-3 ratio compared with the IL-1β-treated group.
Flow cytometry confirmed the anti-apoptotic effect at 100 μM, while crystal violet staining and western blot showed dose-dependent effects at 25, 50, and 100 μM.
Produced similar results in mouse ATDC5 cells.

Western Blot Analysis[3]

Cell Line: primary rat chondrocytes
Concentration: 100 μM
Incubation Time: 24 h
Result: Upregulated Nrf2, HO-1, and GPX4 expression compared with the IL-1β-treated group.
Had its protective effect on GPX4 expression abolished by Nrf2 or HO-1 inhibitors, which exacerbated IL-1β-induced GPX4 suppression.

ELISA Assay[4]

Cell Line: C57BL/6 mouse melanocytes
Concentration: 25 µg/mL
Incubation Time: 1, 2, 4, 6 h post-UVA irradiation
Result: Significantly reduced dark-CPD formation within the first 2 h post-irradiation, with an ~82% reduction observed after 1 h compared to controls.
Matched control CPD levels by 6 h post-irradiation, indicating no interference with DNA repair.
Left cell viability unaffected.
In Vivo

Acetyl zingerone (1 mg/kg; intra-articular injection; twice a week; for 8 consecutive weeks) alleviates osteoarthritis progression induced by the destabilization of the medial meniscus (DMM) model in mice by promoting PINK1/Parkin-mediated mitophagy, inhibiting chondrocyte pyroptosis, reducing cartilage damage, and restoring subchondral bone remodeling[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 J (male, 8-week-old, DMM surgery-induced osteoarthritis)[2]
Dosage: 1 mg/kg
Administration: intra-articular injection; twice a week; 8 weeks
Result: Significantly reduced calcified menisci and bone remnants compared to the DMM-only group.
Normalized subchondral bone microarchitecture parameters, increasing bone volume/tissue volume (BV/TV) and trabecular thickness (Tb.Th) relative to the DMM-only group.
Reduced cartilage loss and proteoglycan depletion, lowering Osteoarthritis Research Society International (OARSI) scores compared to the DMM-only group.
Decreased immunohistochemical staining of pyroptosis-related protein NLRP3 and matrix-degrading protein MMP13 in cartilage tissues relative to the DMM-only group.
Increased immunohistochemical staining of mitophagy-related proteins Parkin and LC3B, as well as matrix-synthesizing protein Collagen II, in cartilage tissues relative to the DMM-only group.
Molecular Weight

236.26

Formula

C13H16O4
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C(C(CC1=CC=C(C(OC)=C1)O)C(C)=O)C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (423.26 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.2326 mL 21.1631 mL 42.3263 mL
5 mM 0.8465 mL 4.2326 mL 8.4653 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 5 mg/mL (21.16 mM); Clear solution

    This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 5 mg/mL (21.16 mM); Clear solution

    This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 4.2326 mL 21.1631 mL 42.3263 mL 105.8156 mL
5 mM 0.8465 mL 4.2326 mL 8.4653 mL 21.1631 mL
10 mM 0.4233 mL 2.1163 mL 4.2326 mL 10.5816 mL
15 mM 0.2822 mL 1.4109 mL 2.8218 mL 7.0544 mL
20 mM 0.2116 mL 1.0582 mL 2.1163 mL 5.2908 mL
25 mM 0.1693 mL 0.8465 mL 1.6931 mL 4.2326 mL
30 mM 0.1411 mL 0.7054 mL 1.4109 mL 3.5272 mL
40 mM 0.1058 mL 0.5291 mL 1.0582 mL 2.6454 mL
50 mM 0.0847 mL 0.4233 mL 0.8465 mL 2.1163 mL
60 mM 0.0705 mL 0.3527 mL 0.7054 mL 1.7636 mL
80 mM 0.0529 mL 0.2645 mL 0.5291 mL 1.3227 mL
100 mM 0.0423 mL 0.2116 mL 0.4233 mL 1.0582 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Acetyl zingerone Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Acetyl zingerone30881-23-3Interleukin RelatedReactive Oxygen Species (ROS)MMPPyroptosisFerroptosisNotchKeap1-Nrf2PINK1/ParkinMitophagyCaspaseApoptosisILMatrix metalloproteinasesPTEN-induced kinase 1/ParkinMitochondrial AutophagyMMP-12C57BL/6 mouse melanocytesMMP-1primary rat chondrocytesATDC5 chondrocytesNLRP3 inflammasomereconstructed human epidermisMMP-3normal human neonatal epidermal keratinocyteshuman dermal fibroblastsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Acetyl zingerone
Cat. No.:
HY-164826
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.